

## What is XENPOZYME?

XENPOZYME is an enzyme replacement therapy containing olipudase alfa as the active ingredient. It is used as a replacement for an enzyme called acid sphingomyelinase (ASM), which is lacking in patients with ASM deficiency (ASMD). In such patients, the activity of ASM is either lower than normal or absent completely, which can cause various symptoms. XENPOZYME is indicated as an enzyme replacement therapy for the treatment of non-central nervous system manifestations of ASMD in paediatric and adult patients with type A/B or type B.

## For women of childbearing potential including adolescents

It is recommended to perform a pregnancy test prior to treatment initiation.

It is advised to use effective contraception during treatment and for 14 days after the last dose if olipudase alfa is discontinued.

Discuss the need for effective contraception with your treating physician.

Contact your treating physician if you suspect you might be pregnant or if you plan pregnancy.

Patient's name:

Treating physician:

Name:

Contact (telephone):

Hospital:

Name:

Emergency contact (telephone):

## Important side effects

XENPOZYME is given as an intravenous infusion. In rare cases, during or after infusion, patients may experience a severe allergic reaction, which must be treated immediately.

Seek urgent medical attention if any of the following signs and symptoms appear or worsen during or after infusion:

- Shortness of breath/ choking
- Dizziness, weakness or fainting
- Weak and rapid pulse
- Nausea, vomiting or diarrhea
- Flushed and pale skin, hives, itching

Please report any events to your treating physician.

## XENPOZYME (olipudase alfa)

## PATIENT CARD



This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information.

Healthcare professionals are asked to report any suspected adverse events at [www.tga.gov.au/reporting-problems](http://www.tga.gov.au/reporting-problems).

This Patient Card contains important information you need to be aware of when receiving treatment with XENPOZYME. Please refer to the Consumer Medicines Information for complete information, available at <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2023-CMI-02154-1&d=20231012172310101> or by contacting 1800 818 806

### General guidance

Please show this card to any treating physician involved in your medical care.

## XENPOZYME (olipudase alfa)